LONA LeonaBio, Inc.

Nasdaq Biological Products, (No Diagnostic Substances) CIK: 0001620463
AI RATING
SELL
75% Confidence

Investment Thesis

LeonaBio is a pre-revenue stage biotech company with significant cash burn (-$20.9M per period) and only $32.8M in cash reserves, providing limited runway of approximately 1.5 periods before requiring additional capital. While the balance sheet is unlevered with no debt and strong liquidity ratios, the lack of revenue, negative profitability across all metrics, and substantial insider activity suggest elevated execution and dilution risks that outweigh the modest cash cushion.

Strengths

  • + Strong cash position of $32.8M with minimal debt (0x debt/equity ratio)
  • + Excellent liquidity ratios (10.38x current ratio) provide near-term operational flexibility
  • + Low capital intensity ($33K capex) reduces infrastructure burden

Risks

  • ! Pre-revenue stage with unproven commercial viability and no market validation
  • ! Critical cash runway of approximately 1.5-2 periods at current burn rate of -$20.9M per period
  • ! Substantial insider activity (20 Form 4 filings in 90 days) suggests leadership changes or stock sales indicating potential concerns

Key Metrics to Watch

Financial Metrics

Revenue
N/A
Net Income
-32.9M
EPS (Diluted)
$-1.73
Free Cash Flow
-20.9M
Total Assets
71.6M
Cash
32.8M

Profitability Ratios

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE -66.8%
ROA -46.0%
FCF Margin N/A

Balance Sheet & Liquidity

Current Ratio
10.38x
Quick Ratio
10.38x
Debt/Equity
0.00x
Debt/Assets
31.1%
Interest Coverage
-8,607.00x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-10T07:35:19.182305 | Data as of: 2026-03-31 | Powered by Claude AI